BioMarin
BioMarin Pharmaceutical Inc., headquartered in the United States, is a leading biotechnology company specialising in innovative therapies for rare genetic diseases. Founded in 1997, BioMarin has established itself as a pioneer in the industry, focusing on the development of enzyme replacement therapies and gene therapies that address unmet medical needs. With a strong presence in North America, Europe, and Asia, BioMarin's core products include treatments for conditions such as phenylketonuria (PKU) and mucopolysaccharidosis (MPS). The company is renowned for its commitment to research and development, which has led to several groundbreaking therapies that significantly improve patient outcomes. BioMarin's dedication to rare disease treatment has positioned it as a market leader, earning recognition for its innovative approach and impactful contributions to the biotechnology sector.
DitchCarbon Score
How does BioMarin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BioMarin's score of 25 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BioMarin's reported carbon emissions
BioMarin Pharmaceutical Inc., headquartered in the US, currently does not provide specific carbon emissions data for the most recent year, as no emissions figures are available. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In terms of climate commitments, BioMarin has not outlined any specific reduction targets or initiatives in the provided data. This absence of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or may not have publicly disclosed its commitments. As a member of the pharmaceutical industry, BioMarin operates in a sector increasingly focused on sustainability and carbon reduction. However, without specific data or commitments, it is challenging to assess their current standing in relation to industry standards or peer organisations. Overall, while BioMarin has not yet shared detailed emissions data or reduction targets, the company is likely to be aware of the growing importance of climate action within the pharmaceutical sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BioMarin is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
